ATG7 and chronic myelogenous leukemia, BCR-ABL1 positive: Of clinical importance, we also showed that ATG7 knockdown enhanced the effect of the second generation TKIs nilotinib and dasatinib, suggesting that the combination of specific autophagy inhibition and TKI treatment might lead to deeper response rates in CML patients with increased chance of successful drug discontinuation or even cure.